COMMITTED TO IMPROVING PEOPLE'S LIVES AND REDUCING PREMATURE MORTALITY BY IMPROVING LIVER HEALTH
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
COMMITTED TO IMPROVING PEOPLE'S LIVES AND REDUCING PREMATURE MORTALITY BY IMPROVING LIVER HEALTH
Liver disease is the only major cause of death still increasing
year-on-year.
Even then, statistics about liver disease are understated, mainly
because of the stigma associated with alcohol abuse and viral
hepatitis, but also because the disease can cause multiple organ
dysfunction, which gets recorded as the cause of death rather
than the liver disease itself.
Our Foundation is here to change this.
We are powered by science, we are driven by passion for
humanity, we are the EASL International Liver Foundation.
Prof. Massimo Colombo
Chairman of the Board Together we will overcome barriers to improve and extend life.
H e who has Health, has Hope; and he
who has Hope has Everything
THOMAS CARLYLE
THE FOUNDER THE PERFECT TEAM HIGHLIGHT PROJECTS
In 2016, the European Since its establishment, a Since 2016, the Foundation has
Association for the Study of group of well-recognised trained thousands of
the Liver (EASL), a world- experts in the field of liver healthcare providers; provided
class scientific society disease, public health, law, assistance in disease
dedicated to excellence in finance and international elimination strategy; initiated
liver research and the clinical cooperation joined ranks in the healthcare interventions
management of liver leadership of the Foundation. targeting under-served
disorders, decided to At the operational level, the populations; launched first-in-
establish a Foundation in Foundation is managed kind policy review studies; and
Geneva to advance critical through an independent promoted the creation of a
liver health programming secretariat based in Geneva. world-class scientific
globally. consortium to address the
unmet need for transplantable
liver organs.
The EASL International Liver Foundation | 2020
Accelerating discovery of Providing training and Delivering healthcare Advocating for liver
new therapeutic advances capacity building to interventions health through strategic
healthcare providers public health initiatives
EASL International Liver Foundation | 2020
1 000 000
Over the course of its first two years of establishment, the
Foundation has raised over 1,7 million USD to fund 14
different projects across its 4 programmatic pillars. 750 000
Awareness
27%
500 000
250 000
Viral Hep. Elim.
53%
Education USD 0
13%
Research
7%
EASL International Liver Foundation | 2020
In close cooperation with EASL snd
other key partners, the Foundation
is actively engaged in providing
training and capacity building, with
particular emphasis on resource
limited settings.
Under the leadership of the Royal
Free Hospital in London, an
international scientific consortium
dedicated to the development of a
bio-engineered liver has been
launched under the auspices of the
EASL International Liver
Foundation.
EASL International Liver Foundation | 2020
CONSORTIUM'S AIMS
• Create a 5% bio-engineered liver mass in
1. University College London, London, United Kingdom order to develop “implantable liver tissue”
Institute for Liver and Digestive Health: Professor Massimo Pinzani, Dr Giuseppe Mazza
for the treatment of inherited hepatic
Institute for Child Health: Professor Paolo De Coppi
Centre for Cell, Gene and Tissue Therapeutics: Professor Marc Lowdell
metabolic disorders
2. Centro de Investigacion Biomedica Aragon, Zaragoza, Spain • Create bioengineered bile ducts to be
Professor Pedro Baptista used in liver transplant and congenital
3. University of Cambridge, Cambridge, United Kingdom biliary diseases
Stem Cell Institute: Professor Ludovic Vallier, Dr Fotis Sampaziotis • Create a 30% bio-engineered liver mass
4. Universite’ Catholique Louvain, Brussels, Belgium
for transplantation in patients with acute
Institute of experimental and Clinical Research: Professor Etienne Sokal
5. University of Basel, Basel, Switzerland or acute-on-chronic liver failure.
Stem Cell Center of Competence: Dr Andrea Banfi
6. Utrecht University, Utrecht, The Netherlands FOUNDATION'S ROLE
Faculty of Veterinary Medicine: Dr Bart Spee, Dr Louis Penning
7. University of Edinburgh, Edinburgh, United Kingdom • Over 100,000 Euros have been raised by
MRC Centre for Regenerative Medicine: Professor Stuart Forbes the Foundation through generous private
8. Yale University Medical School, New Haven, CT, USA donations
Yale Liver Center: Professor Mario Strazzabosco
• Going forward it is estimated that the
9. Institut de Duve, Brussels, Belgium
Professor Frederic Le Maigre achievement of the bio-engineered liver
10. Medizinische Hochschule Hannover, Hannover, Max Planck Institute Münster and would require an investment of no less
Hannover Germany than 100 million dollars
EASL International Liver Foundation | 2020
CellBiologyCluster-of-Excellence REBIRTH: Professor Tobias Cantz • The Foundation is setting up a charitable
fund to fund this research.
In partnership with the U.S. Center for Disease Control and Prevention (CDC), the EASL International Liver Foundation is establishing a Center for Excellence in Viral Hepatitis Elimination in conjuntion with the Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia. EASL International Liver Foundation | 2020
In partnership with Progetto Arca Foundation, the EASL International Liver Foundation is currently running a program of screening and linkage to care for migrants in Milan, Italy for viral hepatitis B, C and Delta, as well as, HIV. EASL International Liver Foundation | 2020
EASL International Liver Foundation joined forces with San Patrignano, Europe’s largest drug rehabilitation
community, to hold a one-day Viral Hepatitis Elimination in PWID workshop. By bringing the stakeholders
together, this workshop aimed to not only kick -start the call to action for viral hepatitis elimination among
PWID in Italy but to also set the foundations for the generation of a roadmap for elimination.
EASL International Liver Foundation | 2020NASH is currently
the leading cause
for liver
transplantation in
females. Given the
rate of increase,
NASH will likely rise
to become the
leading indication
for Liver
Transplantation in
males as well.
Non-alcoholic fatty liver disease (NAFLD) currently affects about 1/4 of the global population and this is
expected to rise even further. Despite the high prevalence and serious health consequences of the disease,
it receives very little attention. In partnership with 28 national key opinion leader focal points, the
Foundation is currently conducting a study investigating to what extent governments and key stakeholders
across Euorpe are responding to NAFLD/NASH.
EASL International Liver Foundation | 2020D
tw
a
ivg
s
n
h
re
p
m
o
fig .lc
yld
k rc
ve
s
n
ta
h
Expanding Centers of Leading the development of a
Excellence in viral hepatitis global coalition to raise
elimination to Asia and Africa awareness of the NASH
epidemic
Developing a comprehesive
Establishing the world's frst program to empower key
charitable fund dedicated to stakeholders in the fight
bringing to life a against liver cancer.
bioengieered liver
EASL International Liver Foundation | 2020THOROUGH MATCHING EXPERTISE PLANNING AND
CONSULTATION WITH UNMET NEEDS EXECUTION
Good partnerships often begin with Once a clear unmet need is identified, We are especially committed to
an informal conversation. We always the Foundation will tap into its global bringing demonstrable impact,
welcome the opportunity to meet with expertise network to assemble the engineering scalable solutions and
individuals and organizations necessary resources to address it. contributing to innovation in
committed to advancing liver health. healthcare.MASSIMO COLOMBO JEFFREY V. LAZARUS CHRISTIAN BRECHOT JORDI BRUIX TOM H. KARLSEN
CHAIRMAN VICE-CHAIRMAN BOARD MEMBER BOARD MEMBER BOARD MEMBER
MANAL EL SAYED STEFAN WIKTOR BENOIT MERKT ANDREA SIRONI PHILIP N. NEWSOME MARK THURSZ
BOARD MEMBER BOARD MEMBER BOARD MEMBER BOARD MEMBER BOARD MEMBER BOARD MEMBERMAILING ADDRESS Rue Daubin, 7 CH-1203 Geneva, Switzerland EMAIL ADDRESS info@easl-ilf.org PHONE NUMBER +41 22 552 2497
You can also read
